{
    "clinical_study": {
        "@rank": "151526", 
        "acronym": "CRECAS", 
        "arm_group": [
            {
                "arm_group_label": "Ticlopidine+Ginko biloba", 
                "arm_group_type": "Experimental", 
                "description": "Switch to ticlopidine + ginko biloba"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "Keep clopidogrel"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko\n      biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery\n      stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior\n      than clopidogrel in terms of post-stent ischemic lesions in these patients without serious\n      complications."
        }, 
        "brief_title": "Clopidogrel Resistance and Embolism in Carotid Artery Stenting", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carotid Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Carotid Stenosis", 
                "Constriction, Pathologic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients scheduled for stent implantation due to carotid stenosis\n\n          -  Patients resistant to clopidogrel defined by platelet inhibition rate <20% measured\n             by Verify Now before carotid stenting\n\n          -  Patients with informed consent\n\n        Exclusion Criteria:\n\n          -  Antiplatelet therapy other than aspirin, clopidogrel, or ticlopidine\n\n          -  Unable to perform MRI scans\n\n          -  Patients with hematologic abnormalities including neutrophil <1500/ul, platelet\n             <100,000/uL, or AST/ALT >120 U/L\n\n          -  Unsuitable for participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133989", 
            "org_study_id": "2013-06-123"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticlopidine+Ginko biloba", 
                "description": "ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily", 
                "intervention_name": "Ticlopidine + Ginko biloba", 
                "intervention_type": "Drug", 
                "other_name": "Yuclid"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "description": "clopidogrel bisulfate 97.875mg(75mg as clopidogrel)", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carotid stenosis", 
            "Stenting", 
            "Clopidogrel resistance", 
            "Stroke, ischemic"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "neuroboy@unitel.co.kr", 
                "last_name": "Oh Young Bang, MD", 
                "phone": "82-2-3410-3599"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135710"
                }, 
                "name": "Oh Young Bang"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement", 
        "overall_contact": {
            "email": "neuroboy50@naver.com", 
            "last_name": "Oh Young Bang, MD", 
            "phone": "82-2-3410-3599"
        }, 
        "overall_contact_backup": {
            "email": "sukjae.kim@gmail.com", 
            "last_name": "Suk Jae Kim, MD", 
            "phone": "82-2-3410-1895"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Oh Young Bang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Presence of new ischemic lesion in the ipsilesioinal hemisphere on DWI after carotid stening", 
            "measure": "New ischemic lesion on diffusion-weighted imaging (DWI)", 
            "safety_issue": "No", 
            "time_frame": "within 24 hours after carotid stenting"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133989"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Oh Young Bang", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number and Volume of new ischemic lesions on DWI", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours after carotid stenting"
            }, 
            {
                "measure": "Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD)", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours after carotid stenting"
            }, 
            {
                "measure": "Ischemic stroke or transient ischemic attack (TIA)", 
                "safety_issue": "No", 
                "time_frame": "within 30 days after carotid stenting"
            }, 
            {
                "description": "Change of clopidogrel resistance measured by Verify now (P2Y12)", 
                "measure": "Change of clopidogrel resistance", 
                "safety_issue": "No", 
                "time_frame": "1 day after carotid stenting"
            }, 
            {
                "measure": "Pucture site hematoma", 
                "safety_issue": "Yes", 
                "time_frame": "within 30 days after carotid stenting"
            }, 
            {
                "measure": "Mycocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "within 30 days after carotid stenting"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "within 30 days after carotid stenting"
            }, 
            {
                "description": "Neutrophil <1500/uL Platelet <100,000/uL AST or ALT >120 U/L", 
                "measure": "Hematological abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "within 30 days after carotid stenting"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Yuyu Pharma, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}